Breath analysis for colorectal cancer screening

Altomare, Donato F.

doi:10.1111/codi.13480

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, a wide variety of VOC candidates have been identified in colorectal cancer, probably reflecting the use of varying substrates and analytical platforms 15 . In 2013, the present authors' group published the first study 4 outlining the potential of breath analysis for colorectal cancer screening, using a customized breath sampler and gas chromatography–mass spectrometry (GC‐MS) analysis.…”

Section: Introductionmentioning

confidence: 99%

Chemical signature of colorectal cancer: case–control study for profiling the breath print

et al. 2020

View full text Add to dashboard Cite

Background: Effective screening for colorectal cancer can reduce mortality by early detection of tumours and colonic polyps. An altered pattern of volatile organic compounds (VOCs) in exhaled breath has been proposed as a potential non-invasive diagnostic tool for detection of cancer. The aim of this study was to evaluate the reliability of breath-testing for colorectal cancer screening and early diagnosis using an advanced breath sampler. Methods: The exhaled breath of patients with colorectal cancer and non-cancer controls with negative findings on colonoscopy was collected using the ReCIVA ® Breath Sampler. This portable device is able to capture the alveolar breath fraction without environmental contamination. VOCs were desorbed thermally and analysed by gas chromatography-mass spectrometry. The discriminatory ability of VOCs in detecting colorectal cancer was evaluated by receiver operating characteristic (ROC) curve analysis for each VOC, followed by cross-validation by the leave-one-out method, and by applying stepwise logistic regression analysis. Results: The study included 83 patients with colorectal cancer and 90 non-cancer controls. Fourteen VOCs were found to have significant discriminatory ability in detecting patients with colorectal cancer. The model with the diagnosis of cancer versus no cancer resulted in a statistically significant likelihood of discrimination of 173⋅45 (P < 0⋅001), with an area under the ROC curve of 0⋅979. Cross-validation of the model resulted in a true predictive value for colorectal cancer of 93 per cent overall. Reliability of the breath analysis was maintained irrespective of cancer stage. Conclusion: This study demonstrated that analysis of exhaled VOCs can discriminate patients with colorectal cancer from those without. This finding may eventually lead to the creation of a smart online sensory device, capable of providing a binary answer (cancer/no cancer) and directing to further screening.

show abstract

Section: Introductionmentioning

confidence: 99%

Chemical signature of colorectal cancer: case–control study for profiling the breath print

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Extensive research is going on regarding development and evaluation of novel noninvasive screening tests, using a variety of different approaches, such as stool, blood, urine and breath sample-based testing, while addressing different molecular targets, such as genetic, epigenetic or proteomic markers. [15][16][17][18] With the results provided in our manuscript, expected PPVs and NPVs in different populations for any new test with known sensitivity and specificity can be easily estimated. For example, a blood test based on a 29-gene expression panel, with reported sensitivity of 79.5% and specificity of 90%, 19 would have PPVs of around 4.1% in men and 2.7% in women and NPVs of 99.9% in both genders in the average-risk population of the U.S.…”

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 97%

International variation in the prevalence of preclinical colorectal cancer: Implications for predictive values of noninvasive screening tests and potential target populations for screening

Krilavičiūtė

Stock

Brenner

2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Screening for colorectal cancer (CRC) is implemented in an increasing number of countries. We aimed to assess international variation in the prevalence of preclinical CRC and the resulting variation in positive and negative predictive values (PPVs, NPVs) of existing and potential CRC screening tests in various countries. Using age‐ and sex‐specific CRC incidence data and transition rates from preclinical to clinical CRC we estimated overall and age‐ and sex‐specific prevalence of preclinical CRC in the target population aged 50–74 years in different parts of the world. These prevalence estimates were used to derive PPVs and NPVs for existing and potential noninvasive screening tests with varying levels of sensitivity and specificity. Within all regions and countries, prevalence strongly increases with age and is higher in men than in women. In addition, major variation was seen between regions and countries, with overall prevalence varying between 1 and 0.1%. As a result, PPVs are expected to strongly vary between ∼10% for men in high incidence countries, such as Australia and Germany, and 1% for women in low incidence countries, whereas NPVs are expected to be consistently well above 99%. Variation in CRC prevalence profoundly affects expected PPVs of screening tests, and PPVs should be carefully considered when decisions on screening tests and strategies are made for specific populations and health care systems. Here, we provide estimates of preclinical CRC and expected PPVs and NPVs of noninvasive screening tests, which may enhance the empirical basis for planning of population‐based CRC screening strategies.

show abstract

Aptamer-functionalized MOFs and AI-driven strategies for early cancer diagnosis and therapeutics

Futane,

Jadhav,

Mustafa

et al. 2023

Biotechnol Lett

View full text Add to dashboard Cite

Breath analysis for colorectal cancer screening

Cited by 4 publications

References 12 publications

Chemical signature of colorectal cancer: case–control study for profiling the breath print

Chemical signature of colorectal cancer: case–control study for profiling the breath print

International variation in the prevalence of preclinical colorectal cancer: Implications for predictive values of noninvasive screening tests and potential target populations for screening

Aptamer-functionalized MOFs and AI-driven strategies for early cancer diagnosis and therapeutics

Contact Info

Product

Resources

About